191 related articles for article (PubMed ID: 8726415)
21. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population.
Pantaleo G; Koenig S; Baseler M; Lane HC; Fauci AS
J Immunol; 1990 Mar; 144(5):1696-704. PubMed ID: 2137842
[TBL] [Abstract][Full Text] [Related]
22. Generation of CD4+ cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients.
Tani M; Tanimura H; Yamaue H; Mizobata S; Iwahashi M; Tsunoda T; Noguchi K; Tamai M; Hotta T; Terasawa H
Int J Cancer; 1995 Mar; 60(6):802-7. PubMed ID: 7896449
[TBL] [Abstract][Full Text] [Related]
23. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H
Int J Cancer; 2001 Feb; 91(4):516-22. PubMed ID: 11251975
[TBL] [Abstract][Full Text] [Related]
24. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
25. Effects of anti-CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitro.
Parlevliet KJ; Chamuleau ME; Yong SL; Raasveld MH; ten Berge IJ; Schellekens PT
Clin Exp Immunol; 1995 Feb; 99(2):155-9. PubMed ID: 7851005
[TBL] [Abstract][Full Text] [Related]
26. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
27. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
28. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR
Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917
[TBL] [Abstract][Full Text] [Related]
29. Accessory cell-T cell interactions involved in anti-CD3-induced T4 and T8 cell proliferation: analysis with monoclonal antibodies.
Geppert TD; Lipsky PE
J Immunol; 1986 Nov; 137(10):3065-73. PubMed ID: 3095421
[TBL] [Abstract][Full Text] [Related]
30. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
31. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
32. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody.
Anasetti C; Martin PJ; Storb R; Appelbaum FR; Beatty PG; Davis J; Doney K; Hill HF; Stewart P; Sullivan KM
Transplantation; 1992 Nov; 54(5):844-51. PubMed ID: 1440852
[TBL] [Abstract][Full Text] [Related]
33. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy.
Yacyshyn MB; Poppema S; Berg A; MacLean GD; Reddish MA; Meikle A; Longenecker BM
Int J Cancer; 1995 May; 61(4):470-4. PubMed ID: 7538976
[TBL] [Abstract][Full Text] [Related]
34. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA
Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
[TBL] [Abstract][Full Text] [Related]
35. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
36. Tumor-directed cytotoxicity in multiple myeloma--the basis for an experimental treatment approach with interleukin 2.
Peest D; Leo R; Deicher H
Stem Cells; 1995 Aug; 13 Suppl 2():72-6. PubMed ID: 8520515
[TBL] [Abstract][Full Text] [Related]
37. Bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy.
Itoh H; Kakuta T; Kudo T; Sakonju I; Hohdatsu T; Ebina T; Takase K
J Vet Med Sci; 2003 Mar; 65(3):329-33. PubMed ID: 12679562
[TBL] [Abstract][Full Text] [Related]
38. Functional and molecular aspects of transient T cell unresponsiveness: role of selective interleukin-2 deficiency.
Köller MD; Kiener HP; Aringer M; Graninger WB; Meuer S; Samstag Y; Smolen JS
Clin Exp Immunol; 2003 May; 132(2):225-31. PubMed ID: 12699409
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms by which accessory cells contribute in growth of resting T lymphocytes initiated by OKT3 antibody.
Palacios R
Eur J Immunol; 1985 Jul; 15(7):645-51. PubMed ID: 3924633
[TBL] [Abstract][Full Text] [Related]
40. Evidence for IL-2 independent proliferation in human T cells.
Laing TJ; Weiss A
J Immunol; 1988 Feb; 140(4):1056-62. PubMed ID: 2830333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
